H3 K27M–Mutated Diffuse Midline Glioma: Bridging Molecular Pathology and Clinical Care

In this podcast episode, Craig Horbinski, MD, PhD, and Michael W. Ruff, MD, discuss the evolving diagnosis and management of H3 K27–altered diffuse midline glioma (DMG), emphasizing the importance of molecular testing, multidisciplinary collaboration, and emerging therapeutic strategies, including:

• The molecular and epigenetic characteristics of H3 K27–altered DMG and their implications for tumor classification and diagnosis
• Challenges in distinguishing DMG from other brainstem lesions and the importance of tissue biopsy, molecular profiling, and integrated pathology reporting
• Emerging diagnostic approaches, including cerebrospinal fluid analysis, cell-free DNA testing, and epigenomic profiling
• Current treatment strategies and emerging therapies, including radiotherapy, dordaviprone, and investigational CAR T-cell therapies
• The role of tissue stewardship, multidisciplinary coordination, and postmortem research in advancing diagnosis, selecting treatment, and understanding therapeutic response

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Presenters:
Craig Horbinski, MD, PhD
Chair
Professor and Clinician Investigator of Pathology
Department of Laboratory Medicine and Pathology
Mayo Clinic Florida
Vice Chair, Translational Research, Neuro-Oncology Committee
Alliance for Clinical Trials in Oncology
Jacksonville, Florida

Michael W. Ruff, MD
Assistant Professor of Neurology and Medical Oncology
Mayo Clinic
Rochester, Minnesota

Link to full program:
https://bit.ly/4iPzgQh

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.